caa a22 4500 445338377 CHVBK 20180317142803.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1245/s10434-010-1315-6 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1315-6 A Contemporary Population-Based Assessment of the Rate of Lymph Node Dissection for Penile Carcinoma [Elektronische Daten] [Rodolphe Thuret, Maxine Sun, Giovanni Lughezzani, Lars Budaus, Daniel Liberman, Firas Abdollah, Monica Morgan, Rupinder Johal, Claudio Jeldres, Mathieu Latour, Shahrokh Shariat, François Iborra, Jacques Guiter, Jean-Jacques Patard, Paul Perrotte, Pierre Karakiewicz] Background: The adherence rate to National Cancer Institute (NCI) recommendations regarding inguinal lymph nodes dissection (ILND) in high grade T1 (G3T1) and T2-4 squamous cell carcinoma of the penis (SCCP) is not known. We assessed ILND rates in a North American cohort. Materials and Methods: The 17 registries of the Surveillance, Epidemiology, and End Results (SEER) database included 868 patients with SCCP, diagnosed between 1988 and 2006. Analyses consisted of univariable and multivariable logistic regression models. Results: Overall, 27.6% of patients underwent an ILND. ILND rates were directly proportional with T stage: 19.0%, 30.5%, 30.6%, and 32.6% for, respectively, G3T1, T2, T3, and T4 SCCP (chi-square trend, P=0.01). ILND rates also increased over time and were 19.3, 27.3, 30.7, and 30.8% for respectively, 1988-1995, 1996-2000, 2001-2003, and 2004-2006 periods (chi-square trend, P=0.03). Finally, ILND rates decreased with patient age and were 42.6, 33.2, 24.7, and 7.3% for, respectively, patients aged ≤57, 58-68, 69-78 and ≥79years of age (chi-square trend, P<0.001). All 3 variables (T-stage, year of primary tumor excision and patient age) achieved independent predictor status in multivariable analyses. Conclusions: The overall rate of ILND is low. Nonetheless, there is an upward trend over time. Our data indicate that the adherence to the NCI ILND guidelines is suboptimal. In consequence, ILNDs should be more strongly encouraged. Society of Surgical Oncology, 2010 Thuret Rodolphe Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut Sun Maxine Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut Lughezzani Giovanni Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut Budaus Lars Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut Liberman Daniel Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut Abdollah Firas Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut Morgan Monica Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut Johal Rupinder Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut Jeldres Claudio Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut Latour Mathieu Department of Pathology, University of Montreal, Montreal, Canada aut Shariat Shahrokh Department of Urology, Weill Medical College of Cornell University, New York, NY, USA aut Iborra François Department of Urology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France aut Guiter Jacques Department of Urology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France aut Patard Jean-Jacques Department of Urology, Rennes University, Rennes, France aut Perrotte Paul Department of Urology, University of Montreal, Montreal, Canada aut Karakiewicz Pierre Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 439-446 1068-9265 18:2<439 2011 18 10434 https://doi.org/10.1245/s10434-010-1315-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1315-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Thuret Rodolphe Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut NATIONALLICENCE 700 1- Sun Maxine Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut NATIONALLICENCE 700 1- Lughezzani Giovanni Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut NATIONALLICENCE 700 1- Budaus Lars Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut NATIONALLICENCE 700 1- Liberman Daniel Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut NATIONALLICENCE 700 1- Abdollah Firas Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut NATIONALLICENCE 700 1- Morgan Monica Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut NATIONALLICENCE 700 1- Johal Rupinder Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut NATIONALLICENCE 700 1- Jeldres Claudio Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut NATIONALLICENCE 700 1- Latour Mathieu Department of Pathology, University of Montreal, Montreal, Canada aut NATIONALLICENCE 700 1- Shariat Shahrokh Department of Urology, Weill Medical College of Cornell University, New York, NY, USA aut NATIONALLICENCE 700 1- Iborra François Department of Urology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France aut NATIONALLICENCE 700 1- Guiter Jacques Department of Urology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France aut NATIONALLICENCE 700 1- Patard Jean-Jacques Department of Urology, Rennes University, Rennes, France aut NATIONALLICENCE 700 1- Perrotte Paul Department of Urology, University of Montreal, Montreal, Canada aut NATIONALLICENCE 700 1- Karakiewicz Pierre Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Canada aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 439-446 1068-9265 18:2<439 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer